Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease that mainly causes degeneration of the upper and lower motor neurons, ultimately leading to paralysis and death within three to five years after first symptoms. The pathological mechanisms leading to ALS are still not completely understood. Several biomarker candidates have been proposed in cerebrospinal fluid (CSF). However, none of these has successfully translated into clinical routine. Part of the reason for this failure to translate may relate to differences across laboratories. For this reason, several of the most commonly used ALS biomarker candidates were evaluated on clinically well-defined ALS samples from six European centres in a multicentre sample-collection approach with centralized sample processing. Results showed that phosphorylated neurofilament heavy chain differentiated between ALS and control cases in all centres. We therefore propose that measurement of phosphorylated neurofilaments in CSF is the most promising candidate for translation into the clinical setting and might serve as a benchmark for other biomarker candidates.

Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis / S. Lehnert, J. Costa, M. de Carvalho, J. Kirby, M. Kuzma Kozakiewicz, C. Morelli, W. Robberecht, P. Shaw, V. Silani, P. Steinacker, H. Tumani, P. Van Damme, A. Ludolph, M. Otto. - In: AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION. - ISSN 2167-8421. - 15:5-6(2014 Sep), pp. 344-350. [10.3109/21678421.2014.884592]

Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis

C. Morelli;V. Silani;
2014

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease that mainly causes degeneration of the upper and lower motor neurons, ultimately leading to paralysis and death within three to five years after first symptoms. The pathological mechanisms leading to ALS are still not completely understood. Several biomarker candidates have been proposed in cerebrospinal fluid (CSF). However, none of these has successfully translated into clinical routine. Part of the reason for this failure to translate may relate to differences across laboratories. For this reason, several of the most commonly used ALS biomarker candidates were evaluated on clinically well-defined ALS samples from six European centres in a multicentre sample-collection approach with centralized sample processing. Results showed that phosphorylated neurofilament heavy chain differentiated between ALS and control cases in all centres. We therefore propose that measurement of phosphorylated neurofilaments in CSF is the most promising candidate for translation into the clinical setting and might serve as a benchmark for other biomarker candidates.
ALS; CSF biomarker; multicentre sample-collection approach with centralized sample processing; cystatin C; tau; MCP-1; amyloid-beta
Settore MED/26 - Neurologia
Settore BIO/12 - Biochimica Clinica e Biologia Molecolare Clinica
28-feb-2014
Article (author)
File in questo prodotto:
File Dimensione Formato  
Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 822.33 kB
Formato Adobe PDF
822.33 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/232434
Citazioni
  • ???jsp.display-item.citation.pmc??? 25
  • Scopus 58
  • ???jsp.display-item.citation.isi??? 53
social impact